NMI Regulates Adipose Adaptive Thermogenesis Through TLR4/IRF3 Signaling to Promote Obesity
- Adv Sci (Weinh). 2026 Jun 2:e75921. doi: 10.1002/advs.75921.
- 1. Zhongshan School of Medicine, Sun Yat-sen University Shenzhen Campus, Sun Yat-sen University, Shenzhen, China.
- 2. Shenzhen Key Laboratory for Systems Medicine in Inflammatory Disease, Shenzhen, China.
- 3. School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China.
- 4. Laboratory of Metabolism and Aging, School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.
- 5. Department of Pharmacy, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- 6. Guangdong Provincial Key Laboratory of Diabetology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Obesity-associated inflammation is partly driven by damage-associated molecular patterns (DAMPs). However, whether and how these molecules directly restrain energy expenditure and thereby exacerbate metabolic dysfunction remains unclear. Here, we identify N-Myc and STAT interactor (NMI) as a stress-responsive adipokine that suppresses adaptive thermogenesis. NMI expression and secretion are increased in adipocytes exposed to dietary stress and inflammatory cues. Genetic ablation of Nmi protects mice from diet-induced obesity (DIO) through enhanced energy expenditure and cold tolerance driven by augmented brown adipose tissue (BAT) thermogenesis and white adipose tissue (WAT) browning. Mechanistically, adipose tissue-derived NMI activates TLR4/IRF3 signaling, which transcriptionally represses the core thermogenic regulators PPARα, PGC-1α, and UCP1. Therapeutically, neutralization of NMI with a monoclonal antibody ameliorates obesity and reduces adipose tissue macrophage infiltration in DIO mice. Together, our findings establish NMI as an adipokine that couples inflammatory signaling with suppressed energy expenditure, highlighting its therapeutic potential for obesity and associated metabolic disorders.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
target: IKKResearch Areas: Metabolic Disease